May
31
2009
The University of Illinois at Chicago has received nearly $1 million from the U.S. zanamivir mastercard Department of Housing and Urban Development to study the benefits of green healthy housing.
The funding was made available through the American Recovery and Reinvestment Act of 2009.
UIC researchers will evaluate the health and monetary benefits when low-income residents move from distressed, unhealthy public housing into Continue Reading »
May
31
2009
Gilead Sciences, Inc. (Nasdaq:GILD) announced the presentation of data from DAR-311 (DORADO), a Phase III clinical trial evaluating the company’s once-daily oral endothelin receptor antagonist (ERA) darusentan as an add-on treatment for resistant hypertension, defined as the failure to achieve goal blood pressure while adhering to full doses of an appropriate three-drug regimen that includes a diuretic. Continue Reading »
May
31
2009
How employees manage stress at work and in their homes is the focus of Penn State’s portion of a $35 million National Institutes of Health grant that will also test the efficacy of a workplace intervention designed to reduce employee stress and promote well-being.
"We’re seeing that stress in the workplace can create a domino effect that can increase stress and reduce quality of life in families," says David Almeida, professor Continue Reading »
May
30
2009
An international research team has identified a number of unsuspected genetic variants associated with systolic blood pressure (SBP), diastolic blood pressure (DBP), and hypertension (high blood pressure), suggesting potential avenues of investigation for the prevention or treatment of hypertension. The research was funded in part by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Continue Reading »
May
30
2009
Results from an international, placebo-controlled trial,1 presented for the first time at the American Academy of Neurology (AAN) Annual Meeting in Seattle, U.S.A. demonstrate that Mirapexin® / Sifrol® (pramipexole) also improves depressive symptoms, a common, disabling non-motor symptom of Parkinson`s disease (PD), in addition to its established efficacy in treating the motor symptoms of PD.
The "PD-depression" Continue Reading »